OCUL Ocular Therapeutix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCUL

Price (delayed)

$10

Market cap

$2.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$1.68B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on ...

Highlights
The equity has surged by 70% year-on-year but it has declined by 11% since the previous quarter
Ocular Therapeutix's quick ratio has increased by 30% YoY but it has decreased by 12% QoQ
The net income has declined by 39% year-on-year and by 3.8% since the previous quarter
Ocular Therapeutix's gross profit has decreased by 11% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ocutx.com
Peers: ANIK ZBH WST STE

Key stats

What are the main financial stats of OCUL

OCUL stock price

How has the Ocular Therapeutix stock price performed over time
Intraday
-4.76%
1 week
1.32%
1 month
-9.75%
1 year
-18.37%
YTD
-17.63%
QTD
1.83%

Financial performance

How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$52.05M
Gross profit
$45.35M
Operating income
-$313.91M
Net income
-$301.45M
Gross margin
87.1%
Net margin
-579.1%
The net margin has plunged by 51% YoY and by 3.7% from the previous quarter
Ocular Therapeutix's operating margin has decreased by 50% YoY and by 4.8% from the previous quarter
The net income has declined by 39% year-on-year and by 3.8% since the previous quarter
The operating income has contracted by 38% YoY and by 4.8% from the previous quarter

Price vs fundamentals

How does OCUL's price correlate with its fundamentals

Growth

What is Ocular Therapeutix's growth rate over time

Valuation

What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
4.21
P/S
43.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.18
The company's EPS fell by 10% YoY but it rose by 2.8% QoQ
The equity has surged by 70% year-on-year but it has declined by 11% since the previous quarter
OCUL's price to book (P/B) is 69% less than its 5-year quarterly average of 14.4 and 8% less than its last 4 quarters average of 4.8
The stock's P/S is 141% above its 5-year quarterly average of 18.8 and 13% above its last 4 quarters average of 40.3
The revenue has contracted by 8% YoY

Efficiency

How efficient is Ocular Therapeutix business performance
The company's return on sales has shrunk by 54% YoY and by 4% QoQ
OCUL's return on invested capital is down by 42% year-on-year
Ocular Therapeutix's return on equity has increased by 14% YoY and by 7% QoQ
The return on assets has grown by 5% since the previous quarter and by 4.2% year-on-year

Dividends

What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUL.

Financial health

How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets has increased by 49% YoY but it has decreased by 8% QoQ
The current ratio has grown by 30% YoY but it has contracted by 11% from the previous quarter
The debt is 85% less than the equity
The equity has surged by 70% year-on-year but it has declined by 11% since the previous quarter
The company's debt to equity fell by 40% YoY but it rose by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.